Metabolic Parameters and Biomarkers

Metabolic Parameters and Biomarkers


A variety of metabolic parameters and biomarkers can be measured in whole blood, plasma, urine or tissue samples using standard commercially-available kits and reagents :-

Metabolic Parameters and Biomarkers

We also offer the Roche clinical range of assays (including LDL-C and HDL-C) using the Cobas c 111 Analyser. Please click here for further information. 


Blood-samples for measurement of metabolic parameters and biomarkers can be taken from :-


     •     Normal rats or mice or animal models of diabetes or obesity
     •     Following acute or chronic drug treatment (all routes of administration)
     •     Before, during and at the end of chronic studies

Blood samples can be taken by venepuncture or from cannulated rats and we can perform analysis on limited amounts of plasma to enable multiple blood-sampling on the same day.


Liraglutide Improves Glycaemic Control and Lipid Profiles in ZDF Rats


Urine can be collected in metabolism cages to determine :-

     •     Urinary volume and glucose excretion
     •     Urinary markers of kidney damage


Dapagliflozin Increases Urinary Glucose Excretion in Rats


At the end of studies tissues can be collected for measurement of metabolic parameters :-


      •     Pancreatic insulin
      •     Liver glycogen
      •     Liver triglycerides and cholesterol


Our experienced biochemists also offer novel assay development (for transfer to your own labs if required) and can analyse samples from studies performed at other facilities.


Please contact us for further information on our range of standard assays to measure metabolic parameters and biomarkers.




Cheetham et al. 2008. Effect of the MCH1 antagonist, GW803430, on body weight, food and water intake, glucose tolerance, fat pad weight, ex vivo binding and various plasma parameters in dietary-induced obese C57BL/6J mice. Program No. 584.24. Society for Neuroscience Meeting, Washington, DC, 15th-19th November 2008.


Grempler et al. 2010. Weight Loss Induced by the Potent and Selective SGLT-2 Inhibitor, BI 10773, is Due to Body Fat Reduction Studies in Dietary-Induced Obese Rats. Abstract No. 1793-P. American Diabetes Association 70th Scientific Sessions, Orlando, Florida, 25th-29th June 2010.


Grempler et al. 2011. The novel SGLT-2 inhibitor BI 10773 (empagliflozin) prevents pioglitazone-induced weight gain and further improves glycemic control in dietary-induced obese rats. Abstract No. 1851-P. American Diabetes Association 71st Scientific Sessions, San Diego, California, 24th-28th June 2011.


Reiche et al. 2011. Chronic administration of a new dual NEP/ECE inhibitor or lorsartan improves renal function in mice with diabetic nephropathy. Abstract No. 1011-P. American Diabetes Association 71st Scientific Sessions, San Diego, California, 24th-28th June 2011.


Vickers et al. 2011. The DPP-4 inhibitor linagliptin is weight neutral in the DIO rat but inhibits the weight gain of DIO animals withdrawn from exenatide. Abstract No. 979-P. American Diabetes Association 71st Scientific Sessions, San Diego, California, 24th-28th June 2011.


Vickers et al. 2012. Effect of empagliflozin on body weight, glucose control and plasma parameters in STZ-induced diabetic rats fed a high-fat diet: comparison with exenatide. Poster No. 771. European Association for the Study of Diabetes (EASD), Berlin, Germany, 1st-5th October 2012.




Jones et al. 2014. Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats. Eur J Pharmacol 729: 59-66. [PubMed]


Vickers et al. 2014. Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 7: 265-275. [PubMed]